A compelling value story needs a strong product portfolio at its core. But that’s easier said than done, with shorter lifecycles, rising R&D costs, greater demand for evidence, and increasing price sensitivity. Mergers and acquisitions present both opportunities and risks, as high deal values can be difficult to justify, and expected returns can be difficult to realize.

While leading R&D capabilities and a disciplined approach to L&A are essential, well-informed strategies and decision processes are at the heart of developing a robust portfolio. Understanding established and emerging market needs will be increasingly important, and organizations will need to incorporate economic and clinical value considerations early on — for every product in the pipeline and every potential acquisition. With the right insight, medical device executives can focus their resources on bringing the most valuable innovations to market and maximizing returns across the lifecycle.

Numerof can help you focus your efforts on the most valuable opportunities and innovations. Explore our solutions for your industry.